HHS 503A peptide policy hub
91 FR 68526 · Docket No. HHS-OASH-2026-0496FACTS VERIFIED 2026-11-22Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
On October 28, 2026, the US Department of Health and Human Services announced an enforcement-discretion policy: while the 503A Bulks List is developed through rulemaking, state-licensed pharmacies, federal facilities, and licensed physicians may compound with certain peptide bulk drug substances under section 503A without HHS enforcement action. The notice, signed by HHS Secretary Robert F. Kennedy, Jr., was published in the Federal Register on October 30, 2026.
Enforcement discretion: HHS will not enforce against 503A compounders using the six covered peptide bulks while the 503A Bulks List is developed through rulemaking.
It is not approval and it is not binding. It establishes no rights, it can be revisited on any safety signal or product-quality issue, and every drug compounded under it remains unapproved and unreviewed by FDA.
Comment window · deadline roughly November 13, 2026 · official record: the regulations.gov docket
Coverage also calls this the "Interim Access Policy" — the phrase used by the OMB review entry and law-firm advisories. It does not appear in the Federal Register text (which says "interim policy" once). Same instrument; the Federal Register title above is the canonical one.
PCAC recommends all six peptides for the 503A Bulks List
The FDA's Pharmacy Compounding Advisory Committee reviews seven peptides and votes to recommend six — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — over the objections of FDA's own review staff. The vote is advisory, not a rule: it opens the rulemaking sequence that the enforcement-discretion policy later bridges. Site coverage: PCAC vote results.
Policy enters OMB review
The policy sits at the Office of Management and Budget from this date, carried on the OMB review entry as the "Interim Access Policy for Compounding Using Certain Peptides." That label never appears in the published Federal Register text — see the naming note above.
HHS announces the enforcement-discretion policy
HHS announces the policy, signed by Secretary Robert F. Kennedy, Jr. The BBC and US News cover the announcement the same day; US News runs the consumer-facing version most readers will meet — the health department moving to "allow temporary sale of some unapproved peptides."
Federal Register publication — 91 FR 68526
The notice publishes as a notice of availability, opening Docket No. HHS-OASH-2026-0496 for comments via regulations.gov. The FR notice itself names no peptides — the covered-substances list sits in an appendix to the HHS policy document the notice makes available.
Comment window closed
The comment window ran to November 13, 2026 — two weeks after publication, per the notice — and has closed, as consistently reported in post-close law-firm and tracker coverage. The submitted comments remain part of the public record on the regulations.gov docket, which is the official record of what was filed.
503A Bulks List rulemaking
After the window closes, the sequence runs: proposed rule, comment period, final rule — the process through which legal status, not just enforcement posture, actually changes. Law-firm analyses put that sequence at 12 to 24 months from acceptance. The reversion trigger stays live throughout: on its own terms, any safety signal or product-quality issue can end the policy.
The Federal Register notice names no peptides. The six above sit in an appendix to the HHS policy document, as consistently reported across independent coverage — and they are the same six substances the FDA's advisory committee took up in July 2026. Per early BPC-157 coverage of the policy, the discretion is framed as appropriate for subcutaneous, intramuscular, oral, and topical routes of administration — a description of the policy document's own scope, nothing more.
The Federal Register notice opened Docket No. HHS-OASH-2026-0496 on regulations.gov; comments were accepted until November 13, 2026, and the window has closed. The docket record — the notice and every filed comment — remains public.
- Open the docket on regulations.gov — the link below goes straight to it.
- Read the notice before commenting. The caveats above — non-binding, no rights established, revisitable on any safety signal — are the document's own framing and the part most social-media summaries drop.
- Submit your comment through the docket before the window closes. Comments are published on the docket as part of the public record.
This page is informational, not advocacy: whether to comment and what to say is yours to decide. Nothing here is legal or medical advice, and the docket page — not this page or any summary of it — is the official record of dates and requirements.
The notice does not address that question. What moved on October 28, 2026 is the federal government's enforcement posture toward 503A compounders — not the approval status of any peptide, and not what any individual may lawfully buy. Under the policy, state-licensed pharmacies, federal facilities, and licensed physicians may compound with these bulks under section 503A without HHS enforcement action while the 503A Bulks List is developed through rulemaking. Compounded drugs made under it remain unapproved and unreviewed by FDA.
No. Nothing in the notice makes a compounded peptide reviewed, approved, or right for any particular person. Every drug compounded under the policy remains unapproved and unreviewed by FDA. What the rulemaking that follows could change is legal status for compounding — through the sequence of proposal, comment period, and final rule — if it concludes in a final rule adding any of the six to the 503A Bulks List.
It is not binding and it establishes no rights. On its own terms it can be revisited on any safety signal or product-quality issue — a reversion trigger that stays live for the whole life of the policy, regardless of how the rulemaking proceeds.
No. The notice is addressed to compounders — state-licensed pharmacies, federal facilities, and licensed physicians — not to buyers. US News framed it as the health department moving to "allow temporary sale of some unapproved peptides," a consumer-facing reading of an instrument that does not address consumers. The warning letters, prosecutions, and closures in our peptide vendor tracker belong to a lane this notice does not touch, and what an individual may lawfully buy is a separate question covered by our peptide legal status guide.
Not in the Federal Register notice — it names no peptides. The covered substances sit in an appendix to the HHS policy document that the notice makes available. Per that document, as consistently reported across independent coverage, six peptide bulk drug substances are covered: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. They are the same six the FDA's Pharmacy Compounding Advisory Committee took up at its July 23–24, 2026 meeting.
The story returns to rulemaking. The six substances are not on the 503A Bulks List; the notice exists because that list is developed through rulemaking. A proposed rule adding any of the six would start the sequence — proposal, comment period, final rule — through which legal status, not just enforcement posture, actually changes. Law-firm analyses put that sequence at 12 to 24 months from acceptance.
The vote came first. On July 23–24, 2026 the FDA's Pharmacy Compounding Advisory Committee recommended all six of these substances for the 503A Bulks List, over the objections of FDA's own review staff. The enforcement-discretion policy is the bridge across the gap while that recommendation works through rulemaking: HHS is telling 503A compounders it will not enforce against these six bulks in the interim. A committee vote is advisory; a final rule is what would change legal status.
- Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, published October 30, 2026)
- Regulations.gov — Docket HHS-OASH-2026-0496 (submit and read comments — official record)
- HHS — 503A peptide enforcement-discretion policy document, Appendix B (covered-substances list)
- FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- BBC — coverage of the October 28, 2026 HHS peptide announcement
- US News — US Health Department to allow temporary sale of some unapproved peptides (October 28, 2026)
- Partnership for Safe Medicines — critical coverage of the HHS peptide compounding policy (November 2, 2026)
- AJMC — 5 Things to Know About HHS's Interim Peptide Compounding Policy
- Holland & Knight — HHS Issues Interim Enforcement Discretion Policy for Compounding (November 2026)
- Buchanan Ingersoll — what compounding pharmacies need to know about the HHS interim enforcement discretion policy for six peptides
- Scripx — BPC-157 coverage framing the discretion for subcutaneous, intramuscular, oral, and topical routes